Aplastic Anemia

Hematology·MeSH: Anemia, Aplastic

Prevalence

0.5 / 100K

17 drugs in development·10 companies·7 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
felbamate	ANI PHARMACEUTICALS INC (ANIP)
promacta	Novartis AG (NVS)
Promacta	Royalty Pharma plc (RPRX)

Phase 3(7)

Drug	Company
cyclosporine	ENANTA PHARMACEUTICALS INC (ENTA)
cyclosporine	Crinetics Pharmaceuticals, Inc. (CRNX)
cyclosporine	Filana Therapeutics Inc. (FLNA)
cyclosporine	Structure Therapeutics Inc. (GPCR)
Fludarabine	Crinetics Pharmaceuticals, Inc. (CRNX)
horse anti-thymocyte globulin	Crinetics Pharmaceuticals, Inc. (CRNX)
rabbit anti-thymocyte globulin	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(3)

Drug	Company
Haploidentical donor bone marrow transplant	Sanofi (SNY)
rabbit ATG, Cyclosporine, Levamisole	ENANTA PHARMACEUTICALS INC (ENTA)
Unrelated donor bone marrow transplant	Sanofi (SNY)

Phase 1(3)

Drug	Company
2D UC-MSC group	Accustem Sciences Inc. (ACUT)
3D hypoxia-preconditioned UC-MSC group	Accustem Sciences Inc. (ACUT)
hemaxellerate	Regen BioPharma Inc (RGBPP)

Preclinical(1)

Drug	Company
hemaxellarate	Regen BioPharma Inc (RGBPP)

BioSniper tracks 17 drugs in development for Aplastic Anemia across 10 companies.

There are 7 clinical trials targeting Aplastic Anemia tracked by BioSniper.

The estimated prevalence of Aplastic Anemia is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.